Navigation Links
Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
Date:9/8/2008

WALTHAM, Mass., Sept. 8 /PRNewswire/ -- Logical Therapeutics, Inc., announced today the commencement of its double-blind, randomized, active-controlled, multinational study of LT-NS001, a novel prodrug, which is converted in the bloodstream to naproxen, a non-steroidal anti-inflammatory drug (NSAID). NSAIDs are the most common medications taken worldwide for the treatment of pain, inflammation, fever and arthritis, including both rheumatoid arthritis (RA) and osteoarthritis (OA).

"Despite a long history of successfully treating patients for pain and inflammation, NSAIDs have limitations that restrict their use. Gastrointestinal (GI) side effects are a significant safety problem," said Lutz Giebel, Chairman of Logical Therapeutics. Published studies have shown that NSAID use is responsible for 15-60% of hospital admissions for GI bleeding, amounting to approximately 100,000 hospitalizations and 10,000-20,000 deaths annually in the US. "A safer alternative would fulfill a significant unmet medical need," Dr. Giebel went on to say.

In pre-clinical studies in rats and dogs, LT-NS001 was shown to cause significantly less damage to the gastrointestinal tract than equivalent doses of naproxen. The study will assess gastrointestinal injury by endoscopy after 7 days of therapy. LT-NS001 was previously evaluated in two Phase 1 randomized, placebo-controlled, single-dose and multiple-dose pharmacokinetic studies. In all cases, LT-NS001 was well tolerated. Moreover, when the subjects were dosed twice daily with LT-NS001, plasma concentrations of naproxen were within the therapeutic range.

The Company also announced the departure of founding CEO, Dr. Mitchell P. Fink, who resigned to pursue other interests.

About Logical Therapeutics Inc.

Logical Therapeutics, Inc. is a privately held biotechnology company based in Waltham, Massachusetts. Logical Therapeutics is developing drugs to treat a variety of medical conditions that are associate
'/>"/>

SOURCE Logical Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
8. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
9. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
10. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
11. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 2013  PTC Therapeutics, Inc., today announced that it ... the U.S. Securities and Exchange Commission ("SEC") relating to ... The number of shares to be offered and the ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... book-running managers for the offering. Cowen and Company is ...
(Date:5/16/2013)... Mass. and SYDNEY , May ... - ASX: HIN), a leading innovator of less invasive, ... advanced heart failure, today announced that CEO Doug ... UBS Global Healthcare Conference at 11:00 a.m. EDT on Monday, ... 2013 at the Sheraton New York Hotel. A ...
(Date:5/16/2013)... CITY, Calif. , May 16, 2013 AcelRx ... company focused on the development and commercialization of innovative therapies ... that Richard King , President and CEO, ... Conference at the Sheraton New York Hotel in ... Wednesday, May 22, 2013 at 9:30 a.m. ET/6:30 a.m. PT. ...
Breaking Medicine Technology:PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 3
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), ... associated with inflammation, today announced that their product candidate ... Research Award at the Third Congress of the European ... Dr. Daniele De Luca, MD, PhDst at the University ...
... Dec. 7, 2010 InfraReDx, Inc. ... imaging technologies, today announced the publication of a case ... stent thrombosis with lipid core plaque as detected by ... first and only FDA-approved system to provide a Chemogram™ ...
Cached Medicine Technology:Varespladib Receives 2010 European Society Pediatric Research Award 2Varespladib Receives 2010 European Society Pediatric Research Award 3InfraReDx Announces Publication of a Case Report in Circulation Highlighting Novel Clinical Finding with LipiScan™ Coronary Imaging System 2
(Date:5/18/2013)... (PRWEB) May 18, 2013 Although obesity ... tumors, the association between obesity and esophageal adenocarcinoma, a ... other obesity-related tumors. As reported on Cancer.gov, ... are almost twice as likely as those of normal ... the relationship between obesity and esophageal cancer is not ...
(Date:5/18/2013)... “Sleep Apnea Diagnostic & Therapeutic Devices Market [Polysomnographs, Respiratory ... Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, Competitive Landscape ... market drivers, restraints, and opportunities in North America, Europe, ... 147 market data tables ... 318 pagesand in-depth TOC of “Sleep Apnea Diagnostic ...
(Date:5/18/2013)... Florida (PRWEB) May 18, 2013 Adolescents, ... also known as “Spice” or “K2” are landing in ... helping to curb this drug epidemic with a ... synthetic marijuana. , According to research from the National ... second-most popular illegal drug among American teenagers. In 2012, ...
(Date:5/18/2013)... DF (PRWEB) May 18, 2013 The ... leading ayurvedic education institution in the West. Program is ... education. , Ayurveda is a healing modality practiced for ... ), it is considered that health begins when an ... profound understanding of their individual needs. Ayurveda aims to ...
(Date:5/18/2013)... Bay, CA (PRWEB) May 18, 2013 ... , has recently completed a stylish renovation that features ... advanced specialties. , From the ground up, this ... improved with fresh flooring, soothing colors and comfortable spa ... been installed, including an Apilus epilator machine. The ...
Breaking Medicine News(10 mins):Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:Rio Salon and Spa, a Beauty Salon in Morro Bay, Undergoes Makeover 2
... new study shows that Multidetector CT (MDCT) without the use of ... This helps in avoiding the need for surgeons to do ... ,In the past, the best way to find ... contrast media then watch to see if and where the contrast ...
... Previous studies have suggested that drinking a lot of coffee ... result in miscarriage or premature delivery. ,A recent ... of a link between caffeine intake and pregnancy outcome. ... 1,000 women in the initial stages of pregnancy who drank ...
... licenses for inexpensive versions of heart disease and AIDS ... pharmaceutical bigwigs. Health Minister, Mongkol Songkhla, confirmed that the ... ,According to the Health Minister, the drugs are meant ... elaborate on whether the drugs would be generic substitutes ...
... have discovered that learning appears to slow the development of ... The finding suggests that the elderly, by keeping their minds ... The study appears in the Jan. 24 issue of the ... modified mice is the first to show that short but ...
... of the mineral selenium appear to reduce or slow ... selenium have been noted in HIV-positive patients, and evidence ... system function, the researchers report in the Jan. 22 ... ,"Those individuals who were treated with selenium displayed ...
... equally effective alternative therapy for controlling hot flushes and ... derived from progesterone may be as effective as estrogen ... synthetic version of the hormone progesterone, was first made ... available in an oral form – said Dr.Jerilynn Prior, ...
Cached Medicine News:Health News:Learning Slows Physical Progression of Alzheimer's Disease: Study 2Health News:Selenium Supplements May Slow Progression of HIV: Report 2Health News:Selenium Supplements May Slow Progression of HIV: Report 3
... red blood cell (nRBC) control for evaluating the ... 755 hematology analyzer in its enumeration of the ... LH 750/LH 755. nRBC-Chex for LH is a ... for LH has a 75-day closed-vial stability and ...
... negative whole blood control to test for ... tests and hemoglobin electrophoresis. Sickle-Chex is compatible ... solubility kits. Sickle-Chex is packaged in a ... dispenses an accurate sample volume. No pipeting ...
... EX.P.R.T. Release Technology essentially eliminates premature ... Unique anatomically designed tapered stent for ... 0.014 Rapid Exchange catheter with 6 ... atraumatic tip,, Radiopaque marker on catheter ...
... is a three-part differential control assayed for all ... Series, T Series, AcT/AcT diff/AcT diff2, MD Series ... 1700, and 1800; ABX Micros 60; and Diatron ... an open-vial stability of 30 days and a ...
Medicine Products: